Ticking Off Investors, Akari CEO Exits Amid Coversin Trial Controversy

Akari, which is looking to ticks to provide a new PNH drug, has seen its CEO resign and investors launch class action suits amid controversy over a Phase II clinical trial for paroxysmal nocturnal hemoglobinuria.